MIMEDX Announces First Quarter 2026 Operating & Financial Results
MIMEDX reported Q1 net sales of $59 million, a 33% decrease from the prior year, driven by new Medicare reimbursement policies that caused significant market disruption and confusion. Due to these headwinds, the company lowered full-year 2026 sales guidance to a range of $260 to $290 million and expects Adjusted EBITDA to be approximately breakeven.
Key figures
- Revenue
- 59000000
- Guidance
- 2026 net sales $260-$290 million, Adjusted EBITDA approximately breakeven
- Revenue Yoy
- -33%
- Wound decline
- 60%
- Surgical growth
- 13%
- Annualized savings
- $40 million
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.